Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
OBJECTIVE
The present study analyzes the potential of various pro- and anti-inflammatory mediators as markers of disease activity and specificity of Crohn's disease and the interrelations between these inflammatory mediators and the acute phase proteins serum amyloid A (SAA) and C-reactive protein (CRP).


METHODS
Forty patients with active Crohn's disease were prospectively studied three times at 2-month intervals. Twenty patients with active ulcerative colitis and twenty healthy volunteers served as controls. IL-1 alpha, IL-1RA, IL-2, IL-2R, IL-6, IL-8, IL-10, TNF-alpha, ICAM-1, and SAA were determined using ELISA techniques.


RESULTS
IL-6 was one of the various inflammatory mediators which was increased most frequently (> or = 90%) and markedly in active Crohn's disease. From the acute phase proteins and the other conventional markers of disease activity studied, SAA proved most sensitive (> or = 90%) and also showed the closet correlation with CDAI and histological activity. IL-6 was tightly linked to both SAA and CRP (r approximately 0.8). SAA and CRP were closely associated with each other (r = 0.88). The pattern and degree of increases in circulating inflammatory mediators was very similar in patients with ulcerative colitis and Crohn's disease. The increases of all inflammatory mediators and acute phase proteins gradually decreased during medical therapy. During follow-up IL-6 and SAA proved most useful to indicate a relapse of Crohn's disease.


CONCLUSIONS
Measurements of circulating IL-6 and SAA proved most useful for clinical monitoring of the activity of Crohn's disease and ulcerative colitis and thus have advantages over conventional markers such as CRP, sedimentation rate and platelet count. IL-6 is probably the main cytokine factor responsible for hepatic induction of acute phase proteins in Crohn's disease. Measurements of circulating levels of all the inflammatory mediators studied are not useful at all for differentiation between Crohn's disease and ulcerative colitis.
Niederau
C
C
Department of Medicine, Gastroenterology, Heinrich-Heine-University of Düsseldorf, Germany.
Backmerhoff
F
F
Schumacher
B
B
Niederau
C
C
D000209:Acute-Phase Proteins / Q000032:analysis*; D000328:Adult; D001053:Apolipoproteins / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D003093:Colitis, Ulcerative / Q000097:blood* / Q000188:drug therapy; D003424:Crohn Disease / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D007375:Interleukin-1 / Q000032:analysis; D015850:Interleukin-6 / Q000032:analysis; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011498:Protein Precursors / Q000097:blood; D012044:Regression Analysis; D000685:Serum Amyloid A Protein / Q000032:analysis; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D000209:Acute-Phase Proteins; D001053:Apolipoproteins; D018836:Inflammation Mediators; D007375:Interleukin-1; D015850:Interleukin-6; D011498:Protein Precursors; D000685:Serum Amyloid A Protein; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein